A combination antibiotic of third-generation cephalosporin Cefoperazone plus Sulbactam, with ~90% efficacy against Gram-positive, Gram-negative, and anaerobic bacteria. Taiwan's first-choice empirical therapy antibiotic.

First-line treatment for severe infections caused by multidrug-resistant Gram-negative bacteria (MDRGNB). Effective for systemic and urinary tract infections. Can be administered via inhalation to enhance lung bactericidal concentration.

Taiwan's latest antibiotic for severe infections caused by multidrug-resistant Gram-negative bacteria (CRAB, CRPA, CRE). Optimal bactericidal choice with no dose adjustment needed for renal dysfunction—safer and more effective.

First-choice antibiotic for multidrug-resistant Gram-positive infections (VRE, MRSA). Second best-selling antibiotic in the United States.

Latest anesthetic sedative from German Paion. Features rapid onset, short recovery, and high controllability. Safer and more stable than traditional propofol.